EP1144005A4 - TREATMENT OF PAPILLOMA VIRUS INFECTIONS - Google Patents

TREATMENT OF PAPILLOMA VIRUS INFECTIONS

Info

Publication number
EP1144005A4
EP1144005A4 EP99966765A EP99966765A EP1144005A4 EP 1144005 A4 EP1144005 A4 EP 1144005A4 EP 99966765 A EP99966765 A EP 99966765A EP 99966765 A EP99966765 A EP 99966765A EP 1144005 A4 EP1144005 A4 EP 1144005A4
Authority
EP
European Patent Office
Prior art keywords
treatment
infection
papilloma virus
virus infections
vlps
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP99966765A
Other languages
German (de)
French (fr)
Other versions
EP1144005A1 (en
EP1144005B1 (en
Inventor
Jian Zhou
Ian Frazer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
Original Assignee
University of Queensland UQ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Queensland UQ filed Critical University of Queensland UQ
Publication of EP1144005A1 publication Critical patent/EP1144005A1/en
Publication of EP1144005A4 publication Critical patent/EP1144005A4/en
Application granted granted Critical
Publication of EP1144005B1 publication Critical patent/EP1144005B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention relates to treatment of papillomavirus infections. Primarily there is provided a method of treatment of an existing papillomavirus (PV) infection which includes the step of administration of PV VLPs selected from the group consisting of PV L1 VLPs and PV L1/L2 VLPs to a patient suffering from the PV infection. Suitably the PV infection is characterised by the presence of epithelial lesions. The major infection which is treated are gential warts caused by HPV 6 and HPV 11.
EP99966765A 1998-12-11 1999-12-13 Treatment of papillomavirus infections Expired - Lifetime EP1144005B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPP7653A AUPP765398A0 (en) 1998-12-11 1998-12-11 Treatment of papillomavirus infections
AUPP765398 1998-12-11
PCT/AU1999/001108 WO2000035478A1 (en) 1998-12-11 1999-12-13 Treatment of papillomavirus infections

Publications (3)

Publication Number Publication Date
EP1144005A1 EP1144005A1 (en) 2001-10-17
EP1144005A4 true EP1144005A4 (en) 2005-02-09
EP1144005B1 EP1144005B1 (en) 2006-11-02

Family

ID=3811858

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99966765A Expired - Lifetime EP1144005B1 (en) 1998-12-11 1999-12-13 Treatment of papillomavirus infections

Country Status (12)

Country Link
US (2) US6867033B1 (en)
EP (1) EP1144005B1 (en)
JP (2) JP5274737B2 (en)
KR (1) KR100617485B1 (en)
AT (1) ATE344053T1 (en)
AU (1) AUPP765398A0 (en)
CA (1) CA2353866C (en)
DE (1) DE69933891T2 (en)
DK (1) DK1144005T3 (en)
NZ (1) NZ512850A (en)
WO (1) WO2000035478A1 (en)
ZA (1) ZA997638B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100629028B1 (en) * 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. Adjuvant Systems and Vaccines
AUPP765398A0 (en) 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
FR2802426B1 (en) * 1999-12-15 2004-04-02 Neovacs USE OF IMMUNOSUPPRESSIVE AND / OR ANGIOGENIC IMMUNOGENIC PROTEINS MADE INACTIVE FOR THE PRODUCTION OF SECRETORY IGAs
AUPR446801A0 (en) 2001-04-18 2001-05-17 University Of Queensland, The Novel compositions and uses therefor
EP1422526A1 (en) * 2002-10-28 2004-05-26 MTM Laboratories AG Method for improved diagnosis of dysplasias
EP1877087B1 (en) 2005-04-15 2013-02-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
JP6920694B2 (en) 2015-12-04 2021-08-18 シアメン ユニバーシティＸｉａｍｅｎ Ｕｎｉｖｅｒｓｉｔｙ Mutation of L1 protein of human papillomavirus type 11
US11389525B2 (en) * 2017-10-27 2022-07-19 Statens Serum Institut Polygene influenza vaccine
WO2023196884A1 (en) 2022-04-06 2023-10-12 Juno Therapeutics, Inc. Detection assay for human papillomavirus (hpv) type 16 (hpv-16)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2194839T3 (en) 1991-07-19 2003-12-01 Univ Queensland PAPILOMAVIRUS VACCINE.
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5888516A (en) * 1994-05-16 1999-03-30 Merck & Co. Inc. Recombinant papillomavirus vaccines
ATE328068T1 (en) * 1994-05-16 2006-06-15 Merck & Co Inc PAPILLOMAVIRUS VACCINE
EP0793752B1 (en) * 1994-09-06 2003-07-09 Scan-Web I/S A method and a system for manufacturing broad airlaid paper webs containing an absorbing powder
AR004464A1 (en) * 1994-11-14 1998-12-16 Merck Sharp & Dohme A METHOD FOR PRODUCING A PAPILOMAVIRUS CAPSIDE PROTEIN
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
US5821087A (en) 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
WO1998010790A1 (en) * 1996-09-11 1998-03-19 Merck & Co., Inc. Papillomavirus vaccine formulation
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
ATE341339T1 (en) * 1996-12-20 2006-10-15 Merck & Co Inc COMPOSITIONS OF RECOMBINANT PAPILLOMAVIRUS VACCINES
PT973546E (en) * 1997-04-08 2004-06-30 Merck & Co Inc STABILIZED FORMULATIONS OF HUMAN PAPILOMA VIRUS
DE19735118C1 (en) * 1997-08-13 1998-08-13 Deutsches Krebsforsch Papilloma virus DNA
US6228368B1 (en) 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
AUPP765398A0 (en) 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LOWE R S ET AL: "HUMAN PAPILLOMAVIRUS TYPE 11 (HPV-11) NEUTRALIZING ANTIBODIES IN THE SERUM AND GENITAL MUCOSAL SECRETIONS OF AFRICAN GREEN MONKEYS IMMUNIZED WITH HPV-11 VIRUS-LIKE PARTICLES EXPRESSED IN YEAST", JOURNAL OF INFECTIOUS DISEASES, CHICAGO, IL, US, vol. 176, no. 5, 1997, pages 1141 - 1145, XP009009603, ISSN: 0022-1899 *
QI Y.M. ET AL.: "Epithelial cells display separate receptors for papillomavirus VLPs and for soluble L1 capsid protein.", VIROLOGY, vol. 216, 1996, pages 35 - 45, XP002298403 *
SUZICH J.A. ET AL.: "Systemic immunizazion with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas", PROC. NATL. ACAD. SCI. USA, vol. 92, December 1995 (1995-12-01), pages 11553 - 11557, XP002298402 *

Also Published As

Publication number Publication date
ZA997638B (en) 2000-07-06
US6867033B1 (en) 2005-03-15
WO2000035478A1 (en) 2000-06-22
CA2353866C (en) 2013-11-19
US7172870B2 (en) 2007-02-06
DK1144005T3 (en) 2007-03-05
NZ512850A (en) 2004-01-30
KR100617485B1 (en) 2006-09-01
AUPP765398A0 (en) 1999-01-14
KR20010103711A (en) 2001-11-23
EP1144005A1 (en) 2001-10-17
DE69933891T2 (en) 2007-06-21
JP2011037902A (en) 2011-02-24
CA2353866A1 (en) 2000-06-22
US20050244433A1 (en) 2005-11-03
JP2002532434A (en) 2002-10-02
JP5274737B2 (en) 2013-08-28
EP1144005B1 (en) 2006-11-02
DE69933891D1 (en) 2006-12-14
ATE344053T1 (en) 2006-11-15

Similar Documents

Publication Publication Date Title
DE60119734D1 (en) HPV-E7 FOR THE TREATMENT OF HUMAN PAPILLOMA VIRUS
EP1246644A4 (en) INDUCTION OF CELLULAR IMMUNE RESPONSES TO HUMAN PAPILLOMA VIRUS USING PEPTIDES AND NUCLEIC ACID COMPOSITIONS
BR9814606A (en) Vaccine formulation and methods of treating an individual infected with an hpv virus and preventing papillomavirus infection
LU91314I2 (en) "Combination of human papillomavirus viroid particles type 6, 11, 16 and 18 (GARDASIL -GilGARD)"
ATE275406T1 (en) METHODS FOR TREATING DELTA HEPATITIS VIRUS INFECTIONS USING BETA-L-2' DEOXY-NUCLEOSIDS
DE69933891D1 (en) TREATMENT OF PAPILLOMA VIRUS INFECTIONS
ID27787A (en) COMPOUND, COMPOSITION AND METHODS FOR TREATMENT OR PREVENTION OF INFECTIONS CAUSED BY VIRUSES AND RELATED DISEASES
AU3475097A (en) Substituted cyclopentane compounds useful as neuraminidase inhibitors
AU2002360592A1 (en) Inhibitors of hepatitis c virus
EP1030547A4 (en) METHOD FOR PREVENTING AND TREATING BACTERIAL INFECTIONS USING CELLULOSE ACETATE PHTHALATE OR HYDROXYPROPPYLMETHYLCELLULOSE SUBSTANCES
EA200401528A1 (en) DERIVATIVES OF DIARYLSULPHIDES, METHOD OF THEIR PRODUCTION AND INTERMEDIATE CONNECTIONS
MX9701183A (en) Method for preparing an influenza virus, antigens obtained and applications thereof.
DE60114620D1 (en) USE OF CELLULOSESULPATE AND OTHER SULFATED POLYSACCHARIDES FOR THE PREVENTION AND TREATMENT OF PAPPILOMA VIRUS INFECTIONS
KR950031060A (en) Pharmaceutical composition for the treatment of osteoporosis
HUP9801334A2 (en) Dna encoding human papilloma virus type 18
ATE186836T1 (en) USE OF 1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL N-ALKYL DERIVATIVES FOR THE TREATMENT OF HEPATITIS B INFECTIONS
ATE402257T1 (en) ANTISENSE AGAINST C-MYC FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE
ATE380034T1 (en) NEW METHOD FOR PRODUCING VIRUS-LIKE PARTICLES OF THE HUMAN PAPILLOMA VIRUS WITH IMPROVED PROPERTIES
AU4149699A (en) Use of inactivated immunosuppressive and/or angiogenic immunogenic proteins, preparation method and pharmaceutical or vaccine uses
AU4602897A (en) Method for treatment of immunodeficiency virus infection
EP0948967A3 (en) Treatment of viral disease in swine
DE69924262D1 (en) METHOD FOR THE PRODUCTION OF YEAST-EXPRESSED HPV TYPS 6 AND 16 KAPSID PROTEINS
ATE179613T1 (en) PREVENTION AND TREATMENT OF CYTOMEGALOVIRUS USING AMINOOPEPTIDASE
RU94038588A (en) Method of secondary immunodeficiency treatment
DE60032272D1 (en) Steam conversion process for the treatment of vacuum gas oil

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010714

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20041227

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIN1 Information on inventor provided before grant (corrected)

Inventor name: FRAZER, IAN,CTR. FOR IMMUNOLOGY & CANCER RES.

Inventor name: ZHOU, JIAN

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061102

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 69933891

Country of ref document: DE

Date of ref document: 20061214

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061231

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070213

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BUECHEL, KAMINSKI & PARTNER PATENTANWAELTE ESTABLI

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070402

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20070803

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061213

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061102

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: THE UNIVERSITY OF QUEENSLAND

Free format text: THE UNIVERSITY OF QUEENSLAND# #ST LUCIA, BRISBANE, QLD 4072 (AU) -TRANSFER TO- THE UNIVERSITY OF QUEENSLAND# #ST LUCIA, BRISBANE, QLD 4072 (AU)

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 69933891

Country of ref document: DE

Representative=s name: GRAMM, LINS & PARTNER PATENT- UND RECHTSANWAEL, DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 17

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 18

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20181218

Year of fee payment: 20

Ref country code: NL

Payment date: 20181220

Year of fee payment: 20

Ref country code: AT

Payment date: 20181221

Year of fee payment: 20

Ref country code: DK

Payment date: 20181218

Year of fee payment: 20

Ref country code: DE

Payment date: 20181220

Year of fee payment: 20

Ref country code: IE

Payment date: 20181219

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20181220

Year of fee payment: 20

Ref country code: GB

Payment date: 20181217

Year of fee payment: 20

Ref country code: FR

Payment date: 20181214

Year of fee payment: 20

Ref country code: CH

Payment date: 20181217

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20181220

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 69933891

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

Effective date: 20191213

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20191212

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20191212

REG Reference to a national code

Ref country code: BE

Ref legal event code: MK

Effective date: 20191213

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20191212

REG Reference to a national code

Ref country code: IE

Ref legal event code: MK9A

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 344053

Country of ref document: AT

Kind code of ref document: T

Effective date: 20191213

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20191213